Effect of androgen-ablation and hormonal cycling on docetaxel (D) clearance in patients with metastatic prostate cancer (MPC)

• DOI: 10.1200/jco.2005.23.16_suppl.4608
• Publication Date: 2017-02-23T13:55:09Z
• Authors: S. D. Baker; H. I. Scher; J. Li; K. W. Beekman; J. Stewart; C. Collins; V. J. Sinibaldi; J. Walczak; R. Pili; M. A. Carducci
• Keywords: 03 medical and health sciences; 0302 clinical medicine; 3. Good health

4608 Background: D is registered for the treatment of MPC at a dose of 75mg/m2 once every 3 wks with daily low-dose prednisone (LDP). Standard treatment involves androgen-ablation (AA) therapy as maintenance with D therapy. Grade 3/4 neutropenia occurs in 32% of patients (pts) with MPC, which is approximately one-half that in lung cancer pts receiving D monotherapy at 75mg/m2. The objective was to evaluate D clearance (CL) in the presence of AA compared to cycling of testosterone (T) in patients with MPC. Methods: Twenty pts receiving AA therapy were treated with D 25–35 mg/m2 (N=16) or D 75 mg/m2 (N=4) (study 1); serial plasma samples were obtained during wk1 (last sample 168h). Ten non-castrate pts received triptorelin immediately followed by D 75 mg/m2 on d1 of wk 1, T gel was administered for 7d during wk 4, and triptorelin and D were given again on d1 of wk 5 (study 2); during wks 1 and 5, serial plasma samples were obtained (last sample 168h). D concentrations were measured using a validated LC/MS/M...